Home » Topics » BioWorld Science

BioWorld Science
RSS

Applied Therapeutics begins phase III study of AT-1001 for diabetic cardiomyopathy

Sep. 5, 2019

European Commission approves Stelara for moderate to severely active ulcerative colitis

Sep. 5, 2019

Tonix begins phase I study of TNX-601 for daytime treatment of PTSD

Sep. 5, 2019

First safety data presented from phase II trial of revacept

Sep. 5, 2019

Idera Pharmaceuticals and Abbvie to collaborate on immunooncology trial

Sep. 5, 2019

Optimized liver-directed gene therapy for Pompe's disease evaluated in vivo

Sep. 5, 2019

New CDK7 inhibitors presented by Ancureall Biomedical Technology (Shanghai)

Sep. 5, 2019

Chinese researchers describe BRD4 inhibitors

Sep. 5, 2019

Beijing Scitech-Mq Pharmaceuticals divulges VEGFR2 and MET inhibitors

Sep. 5, 2019

Medshine Discovery presents new ATR kinase inhibitors

Sep. 5, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...